LipoMag Kit
A powerful & unique transfection kit
This new kit is an association of DreamFect™ Gold and CombiMag reagents. DreamFect™ Gold formulation is a lipofection reagent achieving high transfection efficiency and high transgene expression level. CombiMag is a Magnetofection™ reagent: versatile and improving transfection efficiency without toxicity. The LipoMag Kit combines both of the advantages of lipofection and magnetofection transfection technique to transfect all kind of cells with the best efficiency!
-
Highest transfection efficiency
-
Achieve superior transgene expression than any other reagent
-
Universal: cell lines, primary cells and ideal for hard-to-transfect cells
-
For all nucleic acids applications
-
Non toxic & biodegradable
-
Serum compatible
-
Simple, ready-to use and rapid
LipoMag Kit enhances number of transfected cells (GFP+)
Transfection efficiency A549 cells |
![]() |
LipoMag Kit increases protein production
LipoMag Kit increases protein production
Comparison with competitor |
![]() |
BEAS-2B and COS-7 cells were transfected with Reagent L., DreamFectTM Gold or with LipoMag Kit in a 24-well plate using 0.5µg of DNA. For LipoMag Kit: DreamfectTM Gold ratio and CombiMag ratio were fixed respectively at 3μL and 1μL per μg of DNA per well. Reagent L and DreamFectTM Gold were used according to manufacturer instruction. GFP expression was assessed under fluorescent microscope 24H after transfection. |
LipoMag Kit improves transfection efficiency in primary cells
Percentage of GFP+ cells comparison with competitor |
|
Co- and sequential transfection can be performed with LipoMag Kit
Sequential transfection in HeLa & COS-7 |
|
HeLa and COS 7 cells were first transfected with 0.25 µg of GFP expression plasmid mixed with LipoMag Kit (DreamFect™ Gold: 2 µL/µg DNA for HeLa and 3 µL/µg DNA for COS-7 – 1 µL CombiMag per µg DNA for both cell lines). 1 hour later, cells were sequentially transfected with RFP plasmid under the same conditions. Results were assessed by fluorescence microscopy 24 hours later. |